Brivaracetam
Active ingredient: Brivaracetam
In short: Brivaracetam oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
What is Brivaracetam used for?
Brivaracetam oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Brivaracetam dosage
Monotherapy or Adjunctive Therapy
The recommended dosage for patients 1 month of age and older is included in Table 1. In pediatric patients weighing less than 50 kg, the recommended dosing regimen is dependent upon body weight. When initiating treatment, gradual dose escalation is not required. Dosage should be adjusted based on clinical response and tolerability.
Age and Body Weight | Initial Dosage | Minimum and Maximum Maintenance Dosage
Adults (16 years and older) | 50 mg twice daily
(100 mg per day) | 25 mg to 100 mg twice daily
(50 mg to 200 mg per day)
Pediatric patients weighing 50 kg or more | 25 mg to 50 mg twice daily
(50 mg to 100 mg per day) | 25 mg to 100 mg twice daily
(50 mg to 200 mg per day)
Pediatric patients weighing 20 kg to less than 50 kg | 0.5 mg/kg to 1 mg/kg twice daily
(1 mg/kg to 2 mg/kg per day) | 0.5 mg/kg to 2 mg/kg twice daily
(1 mg/kg to 4 mg/kg per day)
Pediatric patients weighing 11 kg to less than 20 kg | 0.5 mg/kg to 1.25 mg/kg twice daily
(1 mg/kg to 2.5 mg/kg per day) | 0.5 mg/kg to 2.5 mg/kg twice daily
(1 mg/kg to 5 mg/kg per day)
Pediatric patients weighing less than 11 kg | 0.75 mg/kg to 1.5 mg/kg twice daily
(1.5 mg/kg to 3 mg/kg per day) | 0.75 mg/kg to 3 mg/kg twice daily
(1.5 mg/kg to 6 mg/kg per day)
Brivaracetam oral solution can be initiated with either intravenous or oral administration.
Brivaracetam oral solution may be taken with or without food.
Brivaracetam Oral Solution
A calibrated measuring device is recommended to measure and deliver the prescribed dose accurately. A household teaspoon or tablespoon is not an adequate measuring device.
When using brivaracetam oral solution, no dilution is necessary. Brivaracetam oral solution may also be administered using a nasogastric tube or gastrostomy tube.
Discard any unused brivaracetam oral solution remaining after 5 months of first opening the bottle.
Avoid abrupt withdrawal from brivaracetam oral solution in order to minimize the risk of increased seizure frequency and status epilepticus
.
The recommended dosage for patients with hepatic impairment is included in Table 2
. …
How to take Brivaracetam — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).The Medication Guide accompanies the product and can also be accessed by calling 1-888-998-3988.
Suicidal Behavior and Ideation
Counsel patients, their caregivers, and/or families that antiepileptic drugs, including brivaracetam, may increase the risk of suicidal thoughts and behavior, and advise patients to be alert for the emergence or worsening of symptoms of depression; unusual changes in mood or behavior; or suicidal thoughts, behavior, or thoughts about self-harm. Advise patients, their caregivers, and/or families to report behaviors of concern immediately to a healthcare provider
.
Neurological Adverse Reactions
Counsel patients that brivaracetam causes somnolence, fatigue, dizziness, and gait disturbance. These adverse reactions, if observed, are more likely to occur early in treatment but can occur at any time. Advise patients not to drive or operate machinery until they have gained sufficient experience on brivaracetam to gauge whether it adversely affects their ability to drive or operate machinery
. …
Warnings & precautions
Do not take this medicine if: Hypersensitivity to brivaracetam or any of the inactive ingredients in brivaracetam oral solution (bronchospasm and angioedema have occurred)
.
Antiepileptic drugs (AEDs), including brivaracetam oral solution, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. …
Brivaracetam side effects
The following serious adverse reactions are described elsewhere in labeling:
Suicidal Behavior and Ideation
Neurological Adverse Reactions
Psychiatric Adverse Reactions
Hypersensitivity: Bronchospasm and Angioedema
Serious Dermatologic Reactions
Withdrawal of Antiepileptic Drugs
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In all controlled and uncontrolled trials performed in adult epilepsy patients, brivaracetam was administered as adjunctive therapy to 2437 patients. Of these patients, 1929 were treated for at least 6 months, 1500 for at least 12 months, 1056 for at least 24 months, and 758 for at least 36 months. A total of 1558 patients (1099 patients treated with brivaracetam and 459 patients treated with placebo) constituted the safety population in the pooled analysis of Phase 3 placebo-controlled studies in patients with partial-onset seizures (Studies 1, 2, and 3)
. The adverse reactions presented in Table 4 are based on this safety population; the median length of treatment in these studies was 12 weeks. Of the patients in those studies, approximately 51% were male, 74% were Caucasian, and the mean age was 38 years. …
Drug interactions
Co-administration with rifampin decreases brivaracetam plasma concentrations likely because of CYP2C19 induction . Prescribers should increase the brivaracetam dose by up to 100% (i.e., double the dosage) in patients while receiving concomitant treatment with rifampin .
Co-administration with carbamazepine may increase exposure to carbamazepine-epoxide, the active metabolite of carbamazepine. Though available data did not reveal any safety concerns, if tolerability issues arise when co-administered, carbamazepine dose reduction should be considered
.
Because brivaracetam can increase plasma concentrations of phenytoin, phenytoin levels should be monitored in patients when concomitant brivaracetam is added to or discontinued from ongoing phenytoin therapy
.
Brivaracetam provided no added therapeutic benefit to levetiracetam when the two drugs were co-administered
.
About this medicine
The chemical name of brivaracetam is (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1
H-pyrrol-1-yl] butanamide. Its molecular formula is C
11H
20N
2O
2and its molecular weight is 212.29. The chemical structure is:
Brivaracetam is a white to off-white crystalline powder. It is very soluble in water, buffer (pH 1.2, 4.5, and 7.4), ethanol, methanol, and glacial acetic acid. It is freely soluble in acetonitrile and acetone and soluble in toluene. It is very slightly soluble in n-hexane.
Oral Solution
Brivaracetam oral solution contains 10 mg of brivaracetam per mL. The inactive ingredients are sodium citrate, anhydrous citric acid, methylparaben, sodium carboxymethylcellulose, sucralose, sorbitol solution, glycerin, raspberry flavor, and purified water.
How it works: The precise mechanism by which brivaracetam exerts its anticonvulsant activity is not known. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID aef3ee92-e2a6-4135-94b2-b893f893d5f2. Read the full official label on DailyMed.
Related medicines
Gabapentin Lamotrigine Pregabalin Topiramate Levetiracetam Oxcarbazepine Carbamazepine Ciclopirox